Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Jul 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how using smart watches and continuous glucose monitors can help improve heart health in people with coronary heart disease. The researchers want to find out if tracking glucose levels and physical activity through these devices can reduce risks related to heart problems. If you're between the ages of 18 and 74, have completed a cardiac rehabilitation program, and have been diagnosed with coronary heart disease, you might be eligible to participate.
Participants will need to have a smartphone to use during the study and will be asked to share their health information while wearing the devices. It’s important to note that people with certain health issues that limit physical activity, those currently pregnant, or those who are part of another clinical trial cannot join this study. If you decide to participate, you will be contributing to important research that could help improve care for heart patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent signed by the subject
- • Completed outpatient cardiac rehabilitation
- • Diagnosis of coronary heart disease
- • Access to a smartphone for the duration of the study
- • 18 years or older on the date of consent
- Exclusion Criteria:
- • Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders
- • Known or suspected non-compliance
- • Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject
- • Diabetic patients receiving insulin therapy
- • Lack of proficiency with smart phone/watch
- • Current participation in any other clinical trial, which may confound the results of this trial.
- • NYHA (New York Heart Association) class III or IV congestive heart failure
- • Pregnancy
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Jan Gerrit van der Stouwe, Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported